Chinese drugmakers prep for looming semaglutide generics horizon
Chinese pharmaceutical companies are eyeing a lucrative commercial market set to materialise upon the patent expiry for Novo Nordisk’s blockbuster…
News
Trump blames Covid-19 drugmakers for fuelling CDC turmoil
NVIDIA-backed Charm secures $80m to advance AML drug
Oxford University and Ellison Institute link for AI vaccine research
China’s NMPA conditionally approves Boehringer’s tablets for NSCLC
CapVest to buy control of generics giant Stada in €10bn deal
ESC 2025: Novo Nordisk’s Wegovy superior to Zepbound in reducing CV events
Eisai’s Leqembi unlocks at-home dosing with FDA autoinjector approval
